Arrowhead Pharmaceuticals Submits NDA for Plozasiran to Treat Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Advances Innovative Treatment for Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. has reached a pivotal moment in its development pipeline by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for plozasiran, a treatment targeting familial chylomicronemia syndrome (FCS). This severe genetic disorder is characterized by dangerously elevated triglyceride levels, leading to complications such as acute pancreatitis. With no FDA-approved therapies currently available for FCS, Arrowhead's application represents a significant step toward addressing an unmet medical need and showcases the company's commitment to advancing its proprietary Targeted RNAi Molecule (TRiMTM) platform, which has potential applications across various therapeutic areas, including cardiometabolic and liver diseases.

The NDA submission is underpinned by robust clinical data from the SUMMIT program and the Phase 3 PALISADE study, which demonstrate plozasiran's efficacy in significantly reducing triglyceride levels and the risk of acute pancreatitis among patients. Specifically, the PALISADE study reveals an 80% median reduction in triglycerides for patients receiving a 25 mg dose of plozasiran, coupled with an 83% decrease in the risk of acute pancreatitis compared to placebo. These impressive results not only highlight the therapeutic potential of plozasiran but also reinforce Arrowhead's position as a leader in RNA-targeted therapies, reflecting over 15 years of innovation and collaboration with the patient community.

Chris Anzalone, Ph.D., President and CEO of Arrowhead Pharmaceuticals, stresses the importance of this milestone, which marks the culmination of extensive research and development efforts. As the company seeks to expedite access to plozasiran for FCS patients, it plans to apply for additional regulatory approvals in 2025, ensuring that those at high risk of life-threatening complications can benefit from this promising treatment. The positive safety profile of plozasiran, with common treatment-emergent adverse events being abdominal pain and nasopharyngitis, further supports its potential as a viable therapeutic option.

In addition to the NDA submission, Arrowhead Pharmaceuticals has recently presented the efficacy and safety data from the PALISADE study at the American Heart Association Scientific Sessions 2024. This presentation not only underscores the innovative nature of plozasiran but also aims to increase awareness of FCS and the challenges faced by patients living with this condition. As the company prepares for the next steps in the regulatory process, the advancement of plozasiran could herald a new era in the treatment of familial chylomicronemia syndrome, offering hope to patients and their families.

Arrowhead’s focus on addressing rare genetic disorders reflects a broader trend in the pharmaceutical industry, where companies are increasingly investing in specialized treatments that cater to niche patient populations. The successful development and potential approval of plozasiran could serve as a model for future innovations, paving the way for advancements in the treatment landscape of other underserved conditions.